Drug intelligence / Profile preview

fentanyl + midazolam (84bf09)

Development stage
Unknown
Lead developer
University of Texas at Austin
Modality
Small Molecules
Administration
Intranasal
01

Overview

Fentanyl + midazolam is a combination therapy consisting of a potent synthetic opioid analgesic and a short-acting benzodiazepine. Fentanyl acts as a mu-opioid receptor agonist, providing rapid and effective analgesia, while midazolam serves as a positive allosteric modulator of the GABA-A receptor, inducing sedation and anxiolysis. This specific combination is being evaluated by the **University of Texas at Austin** for intranasal administration in pediatric patients. The primary goal of this formulation is to provide effective pain relief and reduce anxiety during minor surgical procedures, such as the repair of facial lacerations, offering a non-invasive alternative to intravenous sedation in the emergency department setting.

Other names
intranasal fentanyl and midazolam combinationintranasal fentanyl spray and intranasal midazolam spray
02

Targets

KOR (Kappa opioid receptor)BZD site (GABA-A receptor benzodiazepine site)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on fentanyl + midazolam (84bf09).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + midazolam (84bf09).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call